JP2014520155A5 - - Google Patents

Download PDF

Info

Publication number
JP2014520155A5
JP2014520155A5 JP2014517144A JP2014517144A JP2014520155A5 JP 2014520155 A5 JP2014520155 A5 JP 2014520155A5 JP 2014517144 A JP2014517144 A JP 2014517144A JP 2014517144 A JP2014517144 A JP 2014517144A JP 2014520155 A5 JP2014520155 A5 JP 2014520155A5
Authority
JP
Japan
Prior art keywords
patent document
compound
kupperman
evaluation
difficult
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014517144A
Other languages
English (en)
Japanese (ja)
Other versions
JP5944986B2 (ja
JP2014520155A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/043485 external-priority patent/WO2012177835A1/en
Publication of JP2014520155A publication Critical patent/JP2014520155A/ja
Publication of JP2014520155A5 publication Critical patent/JP2014520155A5/ja
Application granted granted Critical
Publication of JP5944986B2 publication Critical patent/JP5944986B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014517144A 2011-06-22 2012-06-21 プロテアソーム阻害剤、ならびにそれらの調製、精製、および使用のためのプロセス Expired - Fee Related JP5944986B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161499962P 2011-06-22 2011-06-22
US61/499,962 2011-06-22
PCT/US2012/043485 WO2012177835A1 (en) 2011-06-22 2012-06-21 Proteasome inhibitors and processes for their preparation, purification and use

Publications (3)

Publication Number Publication Date
JP2014520155A JP2014520155A (ja) 2014-08-21
JP2014520155A5 true JP2014520155A5 (cg-RX-API-DMAC7.html) 2015-08-06
JP5944986B2 JP5944986B2 (ja) 2016-07-05

Family

ID=46395746

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014517144A Expired - Fee Related JP5944986B2 (ja) 2011-06-22 2012-06-21 プロテアソーム阻害剤、ならびにそれらの調製、精製、および使用のためのプロセス

Country Status (6)

Country Link
US (1) US20140121182A1 (cg-RX-API-DMAC7.html)
EP (1) EP2723751A1 (cg-RX-API-DMAC7.html)
JP (1) JP5944986B2 (cg-RX-API-DMAC7.html)
CA (1) CA2833775A1 (cg-RX-API-DMAC7.html)
MX (1) MX2013015308A (cg-RX-API-DMAC7.html)
WO (1) WO2012177835A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016003979A (es) * 2013-10-03 2016-06-15 Millennium Pharm Inc Metodo para profilaxis o tratamiento de lupus eritematoso sistemico y/o nefritis lupica.
US9546928B2 (en) 2014-05-30 2017-01-17 General Electric Company Methods for producing strain sensors on turbine components
US10415964B2 (en) * 2014-05-30 2019-09-17 General Electric Company Methods for producing passive strain indicator on turbine components
MA41505A (fr) * 2015-02-11 2017-12-19 Millennium Pharm Inc Nouvelle forme cristalline d'un inhibiteur de protéasome
CZ2015233A3 (cs) 2015-04-03 2016-10-12 Zentiva, K.S. Způsob přípravy Ixazomib citrátu
CZ2015253A3 (cs) 2015-04-15 2016-10-26 Zentiva, K.S. Nové formy Ixazomib citrátu
US10144761B2 (en) 2015-06-19 2018-12-04 Hanlin Scientific Inc. Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis
CN106608883A (zh) * 2015-10-21 2017-05-03 北京大学 蛋白酶体抑制剂mln9708的合成方法
CN106986884A (zh) * 2016-01-20 2017-07-28 成都贝斯凯瑞生物科技有限公司 一种高效的高纯度含硼化合物制备方法
CN105732683B (zh) * 2016-03-25 2018-10-16 南京林业大学 一类羧酸与α氨基酸组成的二肽硼酸及其酯类化合物、制备方法及其用途
CZ2016204A3 (cs) 2016-04-08 2017-11-01 Zentiva, K.S. Formulace Ixazomib citrátu formy 3
CN107400142B (zh) * 2016-05-19 2019-11-19 成都奥璟生物科技有限公司 一种硼酸和硼酸酯类化合物及其应用
CN108440583B (zh) * 2017-01-23 2020-12-04 成都奥璟生物科技有限公司 一种新的硼酸衍生物及其药物组合物
WO2019020099A1 (zh) * 2017-07-28 2019-01-31 成都地奥九泓制药厂 一种硼酸酯化合物、其合成方法及其用途
AU2019315561B2 (en) * 2018-08-02 2024-01-25 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Borate of azetidine derivative

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
DK1756121T3 (da) 2004-03-30 2012-01-09 Millennium Pharm Inc Syntese af borester- og borsyreforbindelser
NZ582693A (en) * 2007-08-06 2012-01-12 Millennium Pharm Inc Boron-containing proteasome inhibitors
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
SG194349A1 (en) 2008-06-17 2013-11-29 Millennium Pharm Inc Boronate ester compounds and pharmaceutical compositions thereof
EP2238973A1 (en) * 2009-04-07 2010-10-13 Cephalon France Lyophilized preparations of proteasome inhibitors

Similar Documents

Publication Publication Date Title
JP2014520155A5 (cg-RX-API-DMAC7.html)
JP2014528601A5 (cg-RX-API-DMAC7.html)
JP2013517798A5 (cg-RX-API-DMAC7.html)
JP2014513484A5 (cg-RX-API-DMAC7.html)
JP2014525291A5 (cg-RX-API-DMAC7.html)
JP2014519662A5 (cg-RX-API-DMAC7.html)
JP2013532488A5 (cg-RX-API-DMAC7.html)
JP2013540293A5 (cg-RX-API-DMAC7.html)
JP2014502322A5 (cg-RX-API-DMAC7.html)
JP2013519136A5 (cg-RX-API-DMAC7.html)
JP2014521827A5 (cg-RX-API-DMAC7.html)
JP2015515410A5 (cg-RX-API-DMAC7.html)
JP2014533241A5 (cg-RX-API-DMAC7.html)
JP2016523701A5 (cg-RX-API-DMAC7.html)
JP2013529804A5 (cg-RX-API-DMAC7.html)
JP2014532727A5 (cg-RX-API-DMAC7.html)
JP2013506057A5 (cg-RX-API-DMAC7.html)
JP2012074699A5 (cg-RX-API-DMAC7.html)
MX359903B (es) Proteínas estructurales de una mutación del parvovirus como vacunas.
JP2019502892A5 (cg-RX-API-DMAC7.html)
JP2014526316A5 (cg-RX-API-DMAC7.html)
JP2017505048A5 (cg-RX-API-DMAC7.html)
JP2014507581A5 (cg-RX-API-DMAC7.html)
JP2014500769A5 (cg-RX-API-DMAC7.html)
JP2014507482A5 (cg-RX-API-DMAC7.html)